BOSTON – Usually the US FDA encourages sponsors to seek its advice. But when it comes to tips on the Right To Try process, the agency appears intent on remaining silent.
Instead, FDA is placing the burden for deciding eligibility for the alternative expanded access pathway entirely on sponsors.







